Director Sells $1.62M in Stock Following Option Exercise
ETON has more than doubled off its 52-week low of $13.085.
Summary
Eton Pharmaceuticals Director Jennifer McKie Adams sold $1.62 million worth of common stock after exercising options, marking another significant insider sale following recent executive dispositions.
Key Events · Ownership and Investor Activity · ETON
-
Director Sells Shares
Jennifer McKie Adams, a Director, sold 50,000 shares of common stock for $1,623,795 at an average price of $32.48 per share.
-
Option Exercise Precedes Sale
The sale followed the exercise of 50,000 options at a strike price of $3.78 per share, totaling $189,000, with the acquired shares immediately disposed of.
-
Continues Insider Selling Trend
This transaction contributes to a recent pattern of insider selling at Eton Pharmaceuticals, with over $7 million in net sales by insiders in the last 90 days, including sales by the CBO and CEO.
Analysis · ETON · Life Sciences
This Form 4 filing indicates a significant open-market sale by Director Jennifer McKie Adams, totaling over $1.6 million. While the sale was preceded by an option exercise, the immediate disposition of all acquired shares suggests a move to monetize equity rather than increase direct ownership. This transaction adds to a recent trend of insider selling at Eton Pharmaceuticals, with other key executives also having sold shares in the past month. Such sales can be interpreted by investors as a lack of conviction in the company's near-term stock price appreciation, despite recent positive news regarding product sales and acquisitions.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 29.1% of the 1703 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ETON was trading at $32.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $897.4M. The 52-week trading range was $13.09 to $35.66. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.